Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2012 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2012 Financial Results and Provides Corporate Update and Fiscal Year 2013 Guidance
Positive Phase III results with trastuzumab emtansine (T-DM1) were presented in a plenary session at ASCO in June; Roche intends to use these data to apply in 2012 for marketing approval of the compound for the use evaluated. ImmunoGen expects up to three additional partner compounds to begin
View HTML
Toggle Summary ImmunoGen, Inc. Announces Trastuzumab Emtansine (T-DM1) Significantly Improved Survival in the EMILIA Phase III Trial
Trastuzumab emtansine significantly improved overall survival (OS) as well as progression-free survival (PFS) in its lead Phase III trial, EMILIA. Separately, the marketing application for trastuzumab emtansine has been submitted to the US FDA, and one is to be submitted shortly to the European
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the following presentations by Company management at upcoming investor
View HTML
Toggle Summary ImmunoGen, Inc. Announces Presentation of New IMGN901 Clinical Data
Phase I evaluation presented established IMGN901 dose being used in Phase II assessment — the NORTH trial — for first-line treatment of small-cell lung cancer (SCLC). IMGN901 able to be administered at full single-agent dose in combination regimen assessed.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Overall Survival Data Reported for Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial
Trastuzumab emtansine reduced risk of death by 32% compared to the standard-of-care treatment arm of the trial. Findings being reported at the ESMO 2012 Congress ( European Society of Medical Oncology ) and published in New England Journal of Medicine . WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Marketing applications submitted for trastuzumab emtansine (T-DM1) in the US and Europe . Meaningful clinical data expected to be reported in coming year — for ImmunoGen compounds, T-DM1, and other partner compounds. ImmunoGen well positioned to advance its wholly owned compounds at least through
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the following presentations by Company management at upcoming
View HTML
Toggle Summary ImmunoGen, Inc. Announces FDA Has Granted Priority Review Status to the Trastuzumab Emtansine (T-DM1) Marketing Application
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech , a member of the Roche Group, has disclosed that the U.S.
View HTML